The Ethics of Anti-aging Clinical Trials
Interventions aiming to slow, stop, or reverse the aging process are starting to enter clinical trials. Though this line of research is nascent, it has the potential to not only prevent prolonged human suffering, but also to extend human well-being. As this line of research develops, it is important to understand the ethical constraints of conducting such research. This paper discusses some of these constraints. In particular, it discusses the ethical difficulties of conducting this research in a way that would produce reliable data regarding the effectiveness of an anti-aging intervention. Clinical trials of such interventions, I argue, will be faced with a dilemma between two confounding variables. Eliminating the variables requires introducing ethically problematic research practices. Thus, researchers must either perform research in ethically problematic ways, or forego the conduct of high-impact clinical research on anti-aging interventions.
KeywordsInformed consent Study design Research ethics Health behavior
- 45 CFR 46, http://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/ [Accessed September 1 2016].
- Carpenter, C. J., 2010. A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Communication, 25(8), pp.661–669. http://dx.doi.org/10.1080/10410236.2010.521906.
- Janz, N. K. & Becker, M. H., 1984. The health belief model: A decade later. Health Education and Behavior, 11(1), pp.1–47. http://heb.sagepub.com/content/11/1/1.abstract.
- Metformin in longevity study—ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02432287 [Accessed September 1 2016].
- The Belmont report. http://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/ [Accessed September 1 2016].
- UMIN-CTR Clinical Trial. https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&action=brows&recptno=R000024575&type=summary&language=E [Accessed September 1 2016].
- WMA declaration of Helsinki, ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/ [Accessed September 1 2016].
- Yoshino, J. et al. (2016). Nicotinamide mononucleotide, a Key NAD+ Intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metabolism, 14(4), pp.528–536. http://dx.doi.org/10.1016/j.cmet.2011.08.014.